Cytomegalovirus infection in intensive care. Treat or ignore them?
Authors:
T. Karvunidis 1,2; T. Reischig 1,2; M. Matějovič 1,2
Authors‘ workplace:
I. interní klinika, Lékařská fakulta v Plzni, Univerzita Karlova a Fakultní nemocnice Plzeň
1; Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova
2
Published in:
Anest. intenziv. Med., 29, 2018, č. 5, s. 275-282
Category:
Intesive Care Medicine - Review Article
Overview
Cytomegalovirus (CMV) reactivation, infection and associated organ dysfunction in immunocompetent critically ill patients is getting into the intensivists’ focus. Although the causal relationship between CMV reactivation and unfavorable outcomes has not been confirmed yet, observational evidence suggests a strong association with higher mortality, prolonged organ support and length-of-stay in intensive care. In addition to these relatively direct consequences, affected patients are more susceptible to the development of nosocomial infections, potentially as a result of complex immunomodulation of the host caused by CMV reactivation. Epidemiology, pathophysiology, clinical manifestation, treatment and prevention of selected herpesviruses in the immunocompetent patients are summarized in the presented review.
KEYWORDS:
cytomegalovirus – infection – immunocompetency – intensive care
Sources
1. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87–91.
2. Limaye AP, Kirby KA, Rubenfeld GD, et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA. 2008;300:413–422.
3. Ziemann M, Sedemund-Adib B, Reiland P, et al. Increased mortality in long-term intensive care patients with active cytomegalovirus infection. 2008;36:3145–3150.
4. Sinclair J. Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol. 2008;41:180–185.
5. Ong DSY, Spitoni C, Klein Klouwenberg PMC, et al. Cytomegalovirus reactivation and mortality in patients with acute respiratory distress syndrome. Intensive Care Med. 2016;42:333–341.
6. Mansfield S, Griessl M, Gutknecht M, et al. Sepsis and cytomegalovirus: foes or conspirators? Med Microbiol Immunol. 2015;204:431–437.
7. Papazian L, Hraiech S, Lehingue S, et al. Cytomegalovirus reactivation in ICU patients. Intensive Care Med. 2016;42:28–37.
8. Bate SL, Dollar SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988–2004. Clin Infect Dis. 2010;50:1439–1447.
9. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725–738.
10. Xiao W, Mindrinos MN, Seok J, et al. A genomic storm in critically injured humans. J Exp Med. 2011;208:2581–2590.
11. Delano MJ, Ward PA. Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest. 2016;126:23–31.
12. Kalil AC, Florescu DF. Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit. Crit Care Med. 2009;37:2350–2358.
13. Heininger A, Haeberle H, Fischer I, et al. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care. 2011;15:R77.
14. Balthesen M, Messerle M, Reddehase MJ. Lungs are a major site of cytomegalovirus latency and recurrence. J Virol. 1993;67:5360–5366.
15. Toorkey CB, Carrigan DR. Immunohistochemical detection of an immediate early antigen of human cytomegalovirus in normal tissues. J Infect Dis. 1989;160:741–751.
16. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673–758.
17. Moss P. The emerging role of cytomegalovirus in driving immune senescence: a novel therapeutic opportunity for improving health in the eldery. Curr Opin Immunol. 2010;22:529–534.
18. Solana R, Tarazona R, Aiello AE. CMV and immunosenescence: from basics to clinics. Immun Ageing. 2012;9:23.
19. McCormic AL. Control of apoptosis by human cytomegalovirus. Curr Top Mircobiol Immunol. 2008;325:281–295.
20. Powers C, DeFilippis V, Malouli D, et al. Cytomegalovirus immune evasion. Curr Top Microbiol Immunol. 2008;325:333–359.
21. Wilkinson GW, Tomasec P, Stanton RJ, et al. Modulation of natural killer cells by human cytomegalovirus. J Clin Virol. 2008;41:206–212.
22. Slobedman B. Virus-encoded homologs of cellular interleukin-10 and their control of host immune response. J Virol. 2009;83:9618–9629.
23. Noda S, Aguirre SA, Bitmansour A, et al. Cytomegalovirus MCK-2 controls mobilization and recruitment of myeloid progenitor cells to facilitate dissemination. Blood. 2006;107:30–38.
24. Vomaske J, Melynchuk RM, Smith PP, et al. Differential ligand binding to a human cytomegalovirus chemokine receptor determines cell type-specific motility. PLoS Pathol. 2009;5:e1000304.
25. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a systematic review. Crit Care. 2009;13:R68.
26. Seckert CK, Griessl M, Buettner JK, et al. Viral latency drives „memory inflation“: a unifying hypothesis linking two hallmarks cytomegalovirus infection. Med Microbiol Immunol. 2012;201:551–566.
27. Campbell J, Trgovcich J, Kincaid M. Transient CD8–memory contraction: a potential contributor to latent cytomegalovirus reactivation. J Leukoc Biol. 2012;92:933–937.
28. Vogel T, Vadonis R, Kuehn J, et al. Viral reactivation is not related to septic complications after major surgical resections. APMIS. 2008;116:292–301.
29. Frantzeskaki FG, Karampi ES, Kottaridi C, et al. Cytomegalovirus reactivation in a general, nonimmunosuppressed intensive care unit population: incidence, risk factors, associations with organ dysfunction, and inflammatory biomarkers. J Crit Care. 2015;30:276–81.
30. Kalil AC, Levitsky J, Lyden E, et al. Meta-analysis: the efficacy of strategiesto prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med. 2005;143:870–880.
31. Al-Omari A, Aljamaan F, Alhazzani W, et al. Cytomegalovirus infection in immunocompetent critically ill adults: literature review. Ann Intensive Med. 2016;6:110.
32. Lisboa LF, Preiksaitis JK, Humar A, et al. Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients. Transplantation. 2011;92:1063–1068.
33. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76–98.
34. Chiche L, Forel JM, Thomas G, et al. Interferon-γ production by natural killer cells and cytomegalovirus in critically ill patients. Crit Care Med. 2012;40:3162–3169.
35. Cantisán S, Lara R, Montejo M, et al. Pretransplant interferon-γ secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation. Am J Transplant. 2013;13:738–745.
36. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant. 2008;8:990–999.
37. Castón JJ, Catisán S, González-Gasca F, et al. Interferon-γ production by CMV-specific CD8+ T lymphocytes provides protection against cytomegalovirus reactivation in critically ill patients. Intensive Care Med. 2016;42:46–53.
38. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:330–360.
39. Durand CM, Marr KA, Arnold CA, et al. Detection of cytomegalovirus DNA in plasma as an adjunct diagnostic for gastrointestinal tract disease in kidney and liver transplant recipients. Clin Infect Dis. 2013;57:1550–1559.
40. Goodman AL, Murray CD, Watkins J, et al. CMV in the gut: a critical review of CMV detection in the immunocompetent host with colitis. Eur J Clin Microbiol Infect Dis. 2015;34:13–18.
41. Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13:93–106.
42. Torre-Cisneros J, Aguado JM, Caston JJ, et al. Management of cytomegalovirus infection in solid organ transplantrecipients: SET/GESITRA-SEIMC/REIPI recommendations. Transplant Rev. 2016;30:119–143.
43. Fernández-Ruiz M, Munos-Codoceo C, López-Medrano F, et al. Cytomegalovirus myoperikarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med. 2008;47:1963–1966.
44. Forel JM, Martin-Loeches I, Luyt CE. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromized: pro. Intensive Care Med. 2014;40:1945–1949.
45. Chanques G, Jaber S. Treating HSV and CMV reactivations in critically ill patients who are not immunocompromized: con. Intensive Care Med. 2014;40:1950–1953.
46. Limaye AP, Stapleton RD, Peng L, et al. Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA. 2017;318:731–740.
47. Cowley NJ, Owen A, Schiels SC, et al. Safety and efficacy of antiviral therapyfor prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med. 2017;177:774–783.
48. Chiche L, Forel JM, Roch A, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med. 2009;37:1850–1857.
49. Kalil AC, Florescu DF. Is cytomegalovirus reactivation increasing the mortality of patients with severe sepsis? Crit Care. 2011;15:138.
50. Humar A, Kumar D, Boivin G, et al. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis. 2002;186:829–833.
Labels
Anaesthesiology, Resuscitation and Inten Intensive Care MedicineArticle was published in
Anaesthesiology and Intensive Care Medicine
2018 Issue 5
Most read in this issue
- Using propofol − what is forbidden, is not (really) allowed ... or what are we risking if we use it in contradiction with the SPC?
- Regional anaesthesia for knee joint surgery – peripheral nerve blocks with minimal impact on motor function of the lower limb
- Effects of infusion solution on blood coagulation
- Cytomegalovirus infection in intensive care. Treat or ignore them?